IL33 and asthma: Furthermore, after administration of itepekimab, a monoclonal antibody directed against IL-33, to patients suffering from moderate to severe asthma in phase 1 and 2 clinical trials, a decrease in blood eosinophils and an improvement in lung function were observed, suggesting that IL-33 may be a promising target for the treatment of asthma [123,124].